PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18448569-2	2008	Pactimibe has two equally dominant clearance pathways forming R-125528 by CYP3A4 and M-1 by CYP2D6 in vitro.	pactimibe	0-9	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	92-98	
18524873-9	2008	The effect of the N-alkyl chain length of pactimibe analogs on their CYP2D6 metabolic stability was plausibly explained by the docking model.	pactimibe	42-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	69-75	
19000552-2	2008	The pharmacokinetics of pactimibe and its pharmacologically inactive plasma metabolite, R-125528, of which the main clearance pathway is CYP2D6, was affected by coadministration of quinidine.	pactimibe	24-33	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	137-143	
19000552-3	2008	The aim of this study was to investigate the influence of CYP2D6 polymorphism on pharmacokinetics of pactimibe and R-125528.	pactimibe	101-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64	
19000552-4	2008	In addition, exposure was examined after multiple doses of pactimibe sulfate in CYP2D6 poor metabolizer (PMs).	pactimibe	59-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86	
19000552-8	2008	After multiple doses of 100 mg pactimibe to CYP2D6 PMs, the accumulation ratio of R-125528 reached 8.8-fold, however, the exposure of R-125528 in CYP2D6 PMs was covered by the exposure in additional metabolite safety testing.	pactimibe	31-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	44-50	
19000552-8	2008	After multiple doses of 100 mg pactimibe to CYP2D6 PMs, the accumulation ratio of R-125528 reached 8.8-fold, however, the exposure of R-125528 in CYP2D6 PMs was covered by the exposure in additional metabolite safety testing.	pactimibe	31-40	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	146-152	
19000552-9	2008	CONCLUSIONS: Although CYP2D6 polymorphism greatly affected the pharmacokinetics of R-125528 rather than pactimibe, the exposure in CYP2D6 PMs after a multiple dose of 100 mg pactimibe sulfate was covered by additional non-clinical metabolite safety testing.	pactimibe	174-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	22-28	
19000552-9	2008	CONCLUSIONS: Although CYP2D6 polymorphism greatly affected the pharmacokinetics of R-125528 rather than pactimibe, the exposure in CYP2D6 PMs after a multiple dose of 100 mg pactimibe sulfate was covered by additional non-clinical metabolite safety testing.	pactimibe	174-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137	
18056254-0	2008	CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.	pactimibe	93-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6